One of the problems with the new subgroup of HER2 low tumors is that using current assays to measure low levels "is like weighing mice on a scale built for elephants," says one expert.
Medscape Medical News
One of the problems with the new subgroup of HER2 low tumors is that using current assays to measure low levels "is like weighing mice on a scale built for elephants," says one expert.
Medscape Medical News
